MD Anderson on oleander in 2002 
Dquixote1217
17 y
2,780
† Cross †
Cancer: What Your Doctor Did Not Tell You
About Ivermectin and Fenbendazole
Parasites Cleanse
Hulda Clark Cleanses
MD Anderson is currently in the middle of what looks to be a very succesful FDA phase I toxicity trial on a new pill form of oleander extract. This would be the second time MD Anderson has been involved in a successful FDA trial for oleader exact. Here is what they had to say back in 2002:
NON-CONFIDENTIAL TECHNOLOGY DESCRIPTION Oleander extracts with potential uses for treating cancer and viral infections Background One aspect of anticancer research is the search for novel, safe, and effective compounds from plants that have therapeutic potential. One such plant is oleander, an ornamental plant found natively in tropical and subtropical climates. Extracts may possibly be used as an anticancer therapeutic, as well as an antiviral agent. These two indications address a tremendous need in the market. The American Cancer Society predicts there will be over 1 million new cases of solid tumors diagnosed in the US in 2002. The cancer therapeutic market is a multibillion-dollar market. Tamoxifen is the main competitor of Anvirzel/oleandrin products. While used mainly only to treat breast cancer (205,000 new diagnosis in the US predicted for 2002), AstraZeneca realized over $500 million in revenues from tamoxifen, while Barr Laboratories reaped over $350 million from its generic tamoxifen. Competitive Advantages Scientists at MD Anderson are investigating oleander extracts as potential anticancer therapeutics. An extract of oleander (Nerium oleander) that contains oleandrin is efficacious in the treatment of tumors. This use is species-specific and is correlated with Na,K-ATPase isoforms. Human, rabbit, and dog tumor cell lines are sensitive. Also, oleandrin is degraded by rodent plasma, but not by human plasma. Additionally, oleandrin raises the intracellular calcium level, releases cytochrome C from mitochondria, and induces apoptosis through a caspase-dependent pathway. Also, oleandrin inhibits the release of the tumor growth factor bFGF from tumors. bFGF has many tumor-proliferating effects including promoting angiogenesis. Oleandrin was determined to block the activation of NF-?B, which in turn blocks the cell-survival function of NF-?B. Further, oleandrin and oleander extracts inhibit the activation of Akt, a cell survival component. In addition, a non-water-soluble fraction of oleander is able to produce oxygen free-radicals in tumor cells, which may contribute to tumor cell injury and death. Oleandrin, particularly when in the context of oleander extract, is able to cross the blood-brain-barrier. Evidence suggests that oleandrin and oleander extract have antiviral activity. Development continues as the oleander extract is nontoxic to normal cells and exhibits multiple antitumor activities such as inducing apoptosis, reducing molecular mechanisms of cell survival, and inhibiting tumor-promoting factor bFGF-2. The inventors plan to use the rabbit adenocarcinoma cell line to test the relative antitumor efficacy in rabbits, followed by analysis of routes of administration, and combination therapies. Reference Link(s):
N/AMDA Ref. No.: MDA02-045 / 11-19-02 / Note: For further information on how oleander works against cancer, see:
Oleander Induces Autophagy - Exclusive Story
More
- Re: MD Anderson on oleander in 2002/... patientadvocate
17 y
2,395
This is a reply to # 1,297,105I can't wait to see if they sabotage this study in the end! Looks like they already have since this study was done six years ago, what are they saying today?
It is too easy to give human beings sub therapeutic doses (or simply pull the plug on a project,) and then when cancer doesn't resolve, report that Oleander doesn't work in human beings.
This is what has been done to ascorbates. The latest hyped study which got way too much press last week concluded that vitamin c and e were ineffective preventatives against disease. The Only catch,...the subjects in the study took a meager 500mg of vitamin c per day. Ok,...how does 500mg of acidic vitamin c even compare with 20,000 mg buffered ascorbate? It can't imagine.
What a waiste of a study and how immoral is the conclusion which did not advertise the pathetically low dosing? So, why hasn't Oleander progressed at M.D. Anderson?
Will M.D. Anderson follow the path of Mt. Sinai and other prestigious cancer centers?
Remember when Sinai cancer center did toxicity trials and animal studies on ESSIAC? Before they would even test it on human beings in placebo trials the medical center demanded the rights to Essiac formula. (THey didn't even offer to pay for this formula.) How ethical is this? Renee Cassie balked at this and thusly, Essiac research was formally sabotaged and ended.
We will see with time if M.D. Anderson pulls a quick one, wont we? After all this initial study was done six years ago, why hasn't it progressed to placebo human trials, it is now 2008 almost 2009? Where's the data?
If they formally promote Oleandrin ever, I will be very surprised. Happy but surprised.
Question:
Does Oleander have any effect upon stage IV cancer, spread to bones?(breast cancer)
More
- Re: MD Anderson on oleander in 2002/... patientadvocate
17 y
2,395
fetched in 0.3906 sec, IP =172.70.131.157, y=1